Skip to main content

Table 3 PTA, SRT, WDS, ART, TOAE, and ABR of the left ear before and after treatment

From: Assessment of auditory function in hepatitis “C” patients managed by combination of sofosbuvir and daclatsavir

Item

Frequency

Pre

Post

T test

P value

PTA

250 Hz

13.83 ± 3.13

13.50 ± 2.98

0.49

0.63

500 Hz

14.00 ± 2.75

13.33 ± 3.56

1.07

0.29

1 kHz

15.00 ± 3.94

15.67 ± 5.83

0.55

0.59

2 kHz

17.00 ± 4.66

16.33 ± 3.93

1.16

0.26

4 kHz

15.00 ± 4.15

17.67 ± 7.04

1.92

0.04*

8 kHz

14.50 ± 3.31

21.17 ± 8.48

4.49

 < 0.001**

SRT

 

14.03 ± 4.52

15.17 ± 2.78

1.42

0.17

WDS

 

98.80 ± 1.86%

98.27 ± 2.02%

2.11

0.24

ART

500 Hz

88.50 ± 6.04

90.50 ± 5.31

3.89

 < 0.001**

1 kHz

87.67 ± 7.16

87.67 ± 6.79

0.00

1.00

2 kHz

89.67 ± 7.98

89.67 ± 7.76

0.00

1.00

4 kHz

89.83 ± 7.13

92.00 ± 8.67

2.36

0.03*

TOAE

0.75–1.25 kHz

9.53 ± 4.50

8.53 ± 3.98

0.67

0.51

1.25–1.75 kHz

15.62 ± 7.28

16.56 ± 9.72

0.67

0.51

1.75–2.50 kHz

13.62 ± 4.70

13.88 ± 5.60

0.38

0.71

2.50–3.50 kHz

10.32 ± 4.89

9.95 ± 5.96

0.38

0.71

3.50–4.50 kHz

12.47 ± 3.07

8.19 ± 4.60

1.09

0.29

Overall

13.32 ± 8.60

11.09 ± 6.64

0.93

0.36

TOAE reproducibility (%)

0.75–1.25 kHz

79.20 ± 16.48

61.73 ± 10.66

2.58

0.02*

1.25–1.75 kHz

89.13 ± 13.53

83.43 ± 22.19

2.47

0.02*

1.75–2.50 kHz

88.43 ± 13.10

86.57 ± 15.20

1.67

0.11

2.50–3.50 kHz

78.23 ± 19.03

70.20 ± 6.40

2.08

0.03*

3.50–4.50 kHz

75.30 ± 15.37

61.43 ± 1.25

2.17

0.02*

Overall

78.83 ± 14.77

71.83 ± 1.88

1.45

0.16

ABR, LRR

Wave I

1.85 ± 0.10

1.87 ± 0.17

0.70

0.49

Wave III

3.98 ± 0.23

4.08 ± 0.35

1.57

0.13

Wave V

5.72 ± 0.18

5.90 ± 0.30

3.19

0.23

Inter peak I–III

2.10 ± 0.19

2.20 ± 0.37

1.61

0.12

Inter peak III–V

1.75 ± 0.17

1.84 ± 0.30

1.79

0.09

Inter peak I–V

3.87 ± 0.21

4.02 ± 0.33

2.85

0.08

ABR (HRR)

Wave V

5.99 ± 0.27

6.16 ± 0.39

2.52

0.08

  1. There were statistically significant differences between the two measures regarding PTA, AR, and TEOAE